Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Inventiva S.A.    IVA   FR0013233012

INVENTIVA S.A.

(IVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
12.4(c) 14.28(c) 13.5(c) 12.62(c) 11.82 Last
92 227 327 948 300 181 288 558 197 239 Volume
-1.59% +15.16% -5.46% -6.52% -6.34% Change
More quotes
Financials
Sales 2020 4,49 M 5,08 M 5,08 M
Net income 2020 -37,3 M -42,3 M -42,3 M
Net cash position 2020 11,9 M 13,5 M 13,5 M
P/E ratio 2020 -10,4x
Yield 2020 -
Sales 2021 1,83 M 2,07 M 2,07 M
Net income 2021 -34,3 M -38,8 M -38,8 M
Net Debt 2021 22,0 M 25,0 M 25,0 M
P/E ratio 2021 -11,9x
Yield 2021 -
Capitalization 484 M 548 M 549 M
EV / Sales 2020 105x
EV / Sales 2021 277x
Nbr of Employees 86
Free-Float 77,4%
More Financials
Company
Inventiva S.A. is a biopharmaceutical company specialized in the treatment of diseases in the fields of fibrosis, lysosomal overload and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor is currently in Phase... 
More about the company
Surperformance© ratings of Inventiva S.A.
Trading Rating : Investor Rating :
More Ratings
Latest news on INVENTIVA S.A.
07/10Inventiva announces trading resumption of its ordinary shares on Euronext Par..
GL
07/10Inventiva announces the pricing of its initial public offering on the Nasdaq ..
GL
07/10Inventiva announces temporary trading halt of its ordinary shares on Euronext..
GL
07/08INVENTIVA S A : announces the filing of an amended registration statement, inclu..
GL
07/07INVENTIVA : announces the decision by the investigator to reduce the number of p..
AQ
07/07INVENTIVA : - H1 2020 Financial Information
AQ
07/06Inventiva Announces the Start of the Roadshow for its Proposed Global Offerin..
GL
07/06H1 2020 Financial Information
GL
07/06Inventiva announces the decision by the investigator to reduce the number of ..
GL
06/22INVENTIVA : files registration statement for proposed initial public offering in..
AQ
06/19Inventiva files registration statement for proposed initial public offering i..
GL
06/18INVENTIVA : Company presentation - Jefferies Virtual Healthcare Conference
PU
06/16INVENTIVA : 's lanifibranor meets the primary and key secondary endpoints in the..
AQ
06/15INVENTIVA : lanifibranor meets the primary and key secondary endpoints in the Ph..
PU
06/15Inventiva's lanifibranor meets the primary and key secondary endpoints in the..
GL
More news
News in other languages on INVENTIVA S.A.
07/10INVENTIVA S A : annonce la mise à disposition d'un prospectus dans le cadre de s..
07/10Inventiva announces trading resumption of its ordinary shares on Euronext Par..
07/10INVENTIVA S A : annonce la reprise des négociations de ses actions ordinaires su..
07/10INVENTIVA : cotation suspendue à l'ouverture
07/10INVENTIVA S A : A suivre aujourd'hui
More news
Chart INVENTIVA S.A.
Duration : Period :
Inventiva S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 17,67 €
Last Close Price 12,62 €
Spread / Highest target 98,1%
Spread / Average Target 40,0%
Spread / Lowest Target -12,8%
EPS Revisions
Managers
NameTitle
Frédéric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Marie Paule Richard Chief Medical Officer
Chris Buyse Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVENTIVA S.A.243.87%548
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955